• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Jules Stein Eye Institute milestones in research

Article

Below is a partial list of the contributions made by researchers at the Jules Stein Eye Institute and the University of California, Los Angeles, over the past 40 years.

Below is a partial list of the contributions made by researchers at the Jules Stein Eye Institute and the University of California, Los Angeles, over the past 40 years.

Late 1960s-Demonstrated the progress of photoreceptor renewal in the retina.

Early 1970s-Investigated the peripheral retina, leading to improved treatments for retinal detachment.

1970s-Pioneered many plastic surgery techniques, including the Madame Butterfly procedure for reconstruction of the lower eyelid, the transcaruncular orbitotomy, and the deep lateral orbital decompression.

1980s-Identified extended contact-lens wear as a risk factor for corneal infections.

1982-Wrote the first paper describing how AIDS reveals itself in the eye.

1984-Created new muscle transposition surgical procedures for the treatment of strabismus.

1990-Pinpointed the role of the orbital pulley system in ocular motility and strabismus.

1992-Originated the use of the antiseptic povidone iodide to prevent postoperative infections and neonatal ophthalmia.

1990s-Developed special magnetic resonance imaging techniques to image eye muscles for more precise diagnosis of complicated cases.

Late 1990s-Recognized the role of stress proteins in the protection of retinal ganglion cell death from glaucoma.

Late 1990s-Created a knockout mouse model for Stargardt's syndrome that scientists are using to develop genetic and drug treatments for retinal disease.

1999-Participated in early clinical trials of anti-vascular endothelial growth factor therapy, which revolutionized therapy for age-related macular degeneration and diabetic retinopathy.

2003-Pinpointed the importance of long-term IOP fluctuation as a risk factor for progressive glaucoma.

Return to: Jules Stein Eye Institute turns 40, plans expansion

Related Videos
J. Peter Campbell, MD, MPH
Expanding accessibility of vision correction with spectacles for children with cranial abnormalities
Elkin: Talking about the importance of pediatric eye health and safety
Identifying 3 barriers keeping families from accessing cataract treatment for their children in India
Edward Manche, MD
© 2024 MJH Life Sciences

All rights reserved.